English, PDF, 192kb
Many policy initiatives have been implemented in Thailand, in recognition of the key role quality plays in strengthening health care systems.
English, PDF, 172kb
Many policy initiatives have been implemented in Malaysia, in recognition of the key role quality plays in strengthening health care systems. Accreditation programmes for hospitals and health care providers and the development of hospital infection control programmes seem to be the most relevant initiatives.
This third edition of Health at a Glance Asia/Pacific presents a set of key indicators of health status, the determinants of health, health care resources and utilisation, health care expenditure and financing and health care quality across 27 Asia/Pacific countries and economies. Drawing on a wide range of data sources, it builds on the format used in previous editions of Health at a Glance, and gives readers a better
English, PDF, 88kb
Highest life expectancy in Japan has been attained through a series of public health actions and universal health coverage.
Les pays de la région Asie/Pacifique doivent redoubler d’efforts pour élargir l’accès à des soins de santé de qualité et abordables.
Turkey underwent a very ambitious reform programme in 2003, the so-called "Health Transformation Programme". Access to healthcare in Turkey has greatly increased with the attainment of Universal Health Coverage, as also demonstrated by improvement in health outcomes, most notably around maternal and child health and infectious diseases. However, despite these significant achievements, Turkey has a significant way to travel to
Mental disorders represent a considerable disease burden, and have a significant impact on the lives of the OECD population, and account for considerable direct and indirect costs. This report argues that even in those OECD countries with a long history of deinstitutionalisation, there is still a long way to go to make community-based mental health care that achieves good outcomes for people with severe mental illness a reality.
The Working Paper sheds light on the extent to which “value” is considered in pricing and/or coverage decisions in 14 OECD member countries. It describes methods used by countries to assess the therapeutic benefits of new products, as well as approaches for economic evaluation, where relevant, and aims to illustrate how value is assessed and what is its impact on pricing and/or reimbursement decisions.
English, PDF, 478kb
This country profile describes in details the Canadian pharmaceutical system, including decision-making processes for regulatory approval, reimbursement and pricing; assessment guidelines; institution and stakeholders involved and specific policies for new high cost drugs, when available.
English, PDF, 527kb
This country profile describes in details the Australian pharmaceutical system, including decision-making processes for regulatory approval, reimbursement and pricing; assessment guidelines; institution and stakeholders involved and specific policies for new high cost drugs, when available.